Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations

Key TakeawaysA Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.Concerns were also raised about the drug's side effects and the number of patients who dropped out of the trial.The news sent shares of Amgen sinking. Amgen (AMGN) shares tanked Tuesday after results from a test of the biotech's experimental weight-loss drug came in below expectations. The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average wei ...